ProTrans
Type 1 Diabetes (Recent Onset)
Key Facts
About NextCell Pharma
NextCell Pharma's mission is to develop and commercialize advanced, off-the-shelf cell therapies for autoimmune and inflammatory diseases, with a primary focus on Type 1 Diabetes. The company has established a unique and de-risked business model, generating foundational revenue from Scandinavia's largest private stem cell bank, Cellaviva, while advancing its lead candidate, ProTrans, through mid-stage clinical trials. Its strategy is built on a patented donor selection algorithm to ensure therapeutic potency and consistency, positioning it as a scalable player in the regenerative medicine field.
View full company profileAbout NextCell Pharma
NextCell Pharma's mission is to develop and commercialize advanced, off-the-shelf cell therapies for autoimmune and inflammatory diseases, with a primary focus on Type 1 Diabetes. The company has established a unique and de-risked business model, generating foundational revenue from Scandinavia's largest private stem cell bank, Cellaviva, while advancing its lead candidate, ProTrans, through mid-stage clinical trials. Its strategy is built on a patented donor selection algorithm to ensure therapeutic potency and consistency, positioning it as a scalable player in the regenerative medicine field.
View full company profile